Nicox: 2024 Shareholder Meeting on June 28

Sophia Antipolis, France, May 24, 2024 – Nicox (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, has officially scheduled its 2024 ordinary shareholder meeting. The event will take place on Friday, June 28th, 2024, at 2:30 pm CEST. The meeting will be held at the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.

In accordance with article R.22.10-23 of the French Code de commerce, essential documents, including a proxy voting form, will be provided to shareholders upon written request. These documents will also be accessible at the company's headquarters and on the Nicox website (www.nicox.com) by June 13th, 2024.

Shareholders have multiple options to cast their votes: they can vote by proxy, via the internet, or by attending the meeting in person. A detailed voting guide, including instructions for internet voting, is available on the company's website. For any queries related to the voting process, shareholders can reach out to the Investor Relations team at ag2024nicox@nicox.com.

Should the initial meeting not achieve the required quorum, a second meeting is scheduled for Monday, July 15th, 2024, at 2:30 pm CEST, at the same location.

About Nicox

Nicox SA is dedicated to developing innovative solutions aimed at preserving vision and improving ocular health. The company's leading clinical development program is NCX 470 (bimatoprost grenod), an innovative nitric oxide-donating bimatoprost eye drop designed to reduce intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension.

Nicox also generates revenue through VYZULTA®, a product for glaucoma, which is exclusively licensed worldwide to Bausch + Lomb, and ZERVIATE®, a treatment for allergic conjunctivitis, which is licensed in various regions including the U.S. through Harrow, Inc., and in China and much of Southeast Asia through Ocumension Therapeutics. 

Headquartered in Sophia Antipolis, France, Nicox is publicly traded on Euronext Growth Paris under the ticker symbol ALCOX and is part of the CAC Healthcare index. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!